OBI licensed “Nectin-4 Human Antibody” rights from Ablexis, LLC

1.Date of occurrence of the event:2023/07/03 2.Counterparty to the contract or commitment: Ablexis, LLC 3.Relationship with the Company: None 4.Starting and ending dates (or rescission date) of the contract or commitment: 2023/07/03 5.Major content (not applicable where rescinded): (1)Based on the increasing importance of Nectin-4 as a novel anti-cancer target, OBI has engaged AlivaMab Discovery […]

This article is password protected.

To view the content, please enter your password in the field below